- Home
- GUTS vs IPSC Comparison
GUTS vs IPSC Comparison
Compare GUTS & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- IPSC
- Stock Information
- Founded
- GUTS 2010
- IPSC 2019
- Country
- GUTS United States
- IPSC United States
- Employees
- GUTS N/A
- IPSC N/A
- Industry
- GUTS
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- GUTS
- IPSC Health Care
- Exchange
- GUTS NYSE
- IPSC Nasdaq
- Market Cap
- GUTS 58.8M
- IPSC 48.2M
- IPO Year
- GUTS 2024
- IPSC 2021
- Fundamental
- Price
- GUTS $1.98
- IPSC $0.56
- Analyst Decision
- GUTS Buy
- IPSC Strong Buy
- Analyst Count
- GUTS 1
- IPSC 5
- Target Price
- GUTS $10.00
- IPSC $3.33
- AVG Volume (30 Days)
- GUTS 210.4K
- IPSC 725.2K
- Earning Date
- GUTS 05-13-2025
- IPSC 05-15-2025
- Dividend Yield
- GUTS N/A
- IPSC N/A
- EPS Growth
- GUTS N/A
- IPSC N/A
- EPS
- GUTS N/A
- IPSC N/A
- Revenue
- GUTS $60,000.00
- IPSC $114,898,000.00
- Revenue This Year
- GUTS N/A
- IPSC $833.10
- Revenue Next Year
- GUTS N/A
- IPSC N/A
- P/E Ratio
- GUTS N/A
- IPSC N/A
- Revenue Growth
- GUTS N/A
- IPSC 8286.72
- 52 Week Low
- GUTS $0.87
- IPSC $0.34
- 52 Week High
- GUTS $7.05
- IPSC $3.46
- Technical
- Relative Strength Index (RSI)
- GUTS 60.25
- IPSC 52.92
- Support Level
- GUTS $1.85
- IPSC $0.53
- Resistance Level
- GUTS $2.00
- IPSC $0.58
- Average True Range (ATR)
- GUTS 0.16
- IPSC 0.04
- MACD
- GUTS -0.01
- IPSC 0.00
- Stochastic Oscillator
- GUTS 59.82
- IPSC 38.02
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.